Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Upton

Showing results (181-190 of 254) with videos related to

Pageof 26
Sort By:
Antimicrobial Agents and Chemotherapy|March 6, 2019
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of TuberculosisJian Xu, Si-Yang Li, Deepak V Almeida, et al.
International Journal of Antimicrobial Agents|March 9, 2023
Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspectsSimon E Koele, Patrick P J Phillips, Caryn M Upton, et al.
Annals of the American Thoracic Society|September 26, 2023
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept StudySaskia Janssen, Caryn M Upton, Veronique R De Jager, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2011
Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulationYu Lu, Meiqin Zheng, Bin Wang, et al.
Journal of Medicinal Chemistry|August 1, 1991
2-Chloro-1-(2,4-dichlorophenyl)-3-(1H-imidazol-1-yl)-2-phenylpropan-1-one hydrochloride, a novel, nonmutagenic antibacterial with specific activity against anaerobic bacteriaJ P Dickens, G J Ellames, N J Hare, et al.
Clinical Pharmacokinetics|June 6, 2022
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with BedaquilineLénaïg Tanneau, Mats O Karlsson, Andreas H Diacon, et al.
Neurology|October 16, 1999
Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathyJ M Shefner, A G Reaume, D G Flood, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 14, 2021
Short dosing intervals during oral challenge increase the risk of severe adverse reactions in children with milk allergyDanbing Ke, Duncan Lejtenyi, Liane Beaudette, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 11, 2025
Standardizing oral food challenge protocols in food protein-induced enterocolitis syndrome (FPIES): A call for consensusMary Grace Baker, J Andrew Bird, Terri Brown-Whitehorn, et al.
The Journal of Infectious Diseases|February 19, 2021
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical DataSaskia E Mudde, Rami Ayoun Alsoud, Aart van der Meijden, et al.
Pageof 26

Showing results (181-190 of 254) with videos related to

Sort By:
Pageof 26
Antimicrobial Agents and Chemotherapy|March 6, 2019
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of TuberculosisJian Xu, Si-Yang Li, Deepak V Almeida, et al.
International Journal of Antimicrobial Agents|March 9, 2023
Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspectsSimon E Koele, Patrick P J Phillips, Caryn M Upton, et al.
Annals of the American Thoracic Society|September 26, 2023
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept StudySaskia Janssen, Caryn M Upton, Veronique R De Jager, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2011
Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulationYu Lu, Meiqin Zheng, Bin Wang, et al.
Journal of Medicinal Chemistry|August 1, 1991
2-Chloro-1-(2,4-dichlorophenyl)-3-(1H-imidazol-1-yl)-2-phenylpropan-1-one hydrochloride, a novel, nonmutagenic antibacterial with specific activity against anaerobic bacteriaJ P Dickens, G J Ellames, N J Hare, et al.
Clinical Pharmacokinetics|June 6, 2022
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with BedaquilineLénaïg Tanneau, Mats O Karlsson, Andreas H Diacon, et al.
Neurology|October 16, 1999
Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathyJ M Shefner, A G Reaume, D G Flood, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 14, 2021
Short dosing intervals during oral challenge increase the risk of severe adverse reactions in children with milk allergyDanbing Ke, Duncan Lejtenyi, Liane Beaudette, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 11, 2025
Standardizing oral food challenge protocols in food protein-induced enterocolitis syndrome (FPIES): A call for consensusMary Grace Baker, J Andrew Bird, Terri Brown-Whitehorn, et al.
The Journal of Infectious Diseases|February 19, 2021
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical DataSaskia E Mudde, Rami Ayoun Alsoud, Aart van der Meijden, et al.
Pageof 26